CZChaojie Zhu

Chaojie Zhu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chaojie Zhu has a total of 64 co-authors. Here are the top co-authors by number of shared publications:

  • Hongjun Li

    State Key Laboratory of Advanced Drug Delivery and Release Systems, Key Laboratory of Advanced Drug Delivery Systems of Zhejiang Province, Liangzhu Laboratory, School of Pharmacy, Zhejiang University, Hangzhou, China

    6 shared publications
  • Qing Wu

    State Key Laboratory of Advanced Drug Delivery and Release Systems Liangzhu Laboratory School of Pharmacy Zhejiang University Hangzhou China

    5 shared publications
  • Zhen Gu

    Zhejiang University

    4 shared publications
  • Tao Sheng

    National Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China

    3 shared publications
  • Xinyuan Shen

    National Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China

    3 shared publications
  • Jiaqi Shi

    Key Laboratory of Advanced Drug Delivery Systems of Zhejiang Province, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China

    2 shared publications

Latest Publications

  • Genetically Unmodified Cells for Drug Delivery and Therapy

    by Bowen Zhang, Ying Chen, Chaojie Zhu, Qiujun Qiu, Zhen Gu, Hongjun Li

    Cell-based drug delivery uses living cells’ advantages, including prolonged circulation, tissue tropism, barrier crossing, and immune compatibility, to improve drug biodistribution, prolong exposure, and enhance efficacy with reduced toxicity. Genetic engineering approaches like CAR-T therapy, while transformative, face significant hurdles, such as genomic risks, immune toxicities like cytokine release syndrome, strict regulations, expensive GMP manufacturing, and lengthy production timelines. These issues have spurred interest in nongenetic strategies that maintain native cell functions through intracellular loading methods (endocytosis, hypotonic loading, physical poration, cell–liposome fusion) and membrane modifications (covalent and noncovalent conjugation). This Review examines the mechanisms, trade-offs, and compatibility of these approaches with various carrier cells such as erythrocytes, platelets, macrophages, neutrophils, T cells, and NK cells. It further discusses key translational challenges, including safety, immunogenicity, donor and batch heterogeneity, manufacturing, cryopreservation, regulatory standardization, and progression from preclinical to clinical stages.

  • Engineered Bacterial Biomaterials for Augmenting Adoptive Immune Cell Therapy Against Solid Tumors

    by Chaojie Zhu, Zhongquan Sun, Qing Wu, Feifan Wang, Lingxiao Zhang, Weilin Wang, Yuan Ding, Hongjun Li

    Adoptive immune cell therapy (ACT) represents one of the most promising strategies in cancer immunotherapy, leveraging genetically engineered immune cells to recognize and eradicate tumor cells with high specificity. Durable remissions have been achieved in hematological malignancies, particularly with CD19‐targeted chimeric antigen receptor T (CAR‐T) cell therapies. However, the efficacy of ACT in solid tumors remains limited due to the immunosuppressive tumor microenvironment, tumor heterogeneity, and poor infiltration and persistence of the effector cells within tumor sites. Bacterial biomaterials, encompassing live bacteria and their acellular platforms, for example, outer membrane vesicles, represent emerging classes of programmable systems capable of reshaping the tumor immune microenvironment. In this review, we briefly illustrate the underlying molecular mechanisms by which bacterial biomaterials remodel the tumor environment and underscore the advances in the use of engineered bacterial biomaterials to enhance the efficacy of ACT in solid tumors, highlighting the underlying basic principles and engineering strategies to augment current adoptive cellular therapies for overcoming their faced dilemmas in solid tumor settings.


  • Open Access

    Interleukin 12-tethered nano-aluminum adjuvant orchestrates environmental immunomodulation to empower cytotoxic T cells against solid tumors

    by Aining Shen, Jing Zhao, Zhenwei Su, Ran Wang, Ying Li, Chaojie Zhu, Qingyuan Zhao, Pinwan Yu, Zhi Ping Xu, Lingxiao Zhang


  • Open Access

    Remolding the tumor microenvironment by bacteria augments adoptive T cell therapy in advanced-stage solid tumors

    by Chaojie Zhu, Chao Liu, Qing Wu, Tao Sheng, Ruyi Zhou, En Ren, Ruizhe Zhang, Zhengjie Zhao, Jiaqi Shi, Xinyuan Shen, et al.

    The intricate tumor microenvironment presents formidable obstacles to the efficacy of adoptive T cell therapy in the management of solid tumors by limiting the infiltration and inducing exhaustion of the transferred T cells. Here, we developed a bacterial-based adjuvant approach that augments the efficacy of adoptive T-cell therapy for solid tumor treatment. Our study reveals that intratumor injection of E. coli MG1655 normalizes tumor vasculatures and reprograms tumor-associated macrophages into M1 phenotype that produce abundant CCL5, together facilitating tumor infiltration of adoptively transferred T cells. The depletion of tumor-associated macrophages or CCL5 neutralization in vivo leads to the significantly decreased solid tumor infiltration of adoptive T cells in the presence of bacteriotherapy. This combinatorial therapy, consisting of E. coli adjuvant and adoptive T-cell therapy, effectively eradicates early-stage melanoma and inhibits the progression of pancreatic tumors. Notably, this dual strategy also strengthened the distal tumor control capabilities of adoptive T-cell therapy through the induction of in situ tumor vaccination. This dual therapeutic approach involving bacterial therapy targeting the interior of solid tumors and adoptive T-cell therapy attacking the tumor periphery exhibits potent therapeutic efficacy in achieving the eradication of advanced-stage tumors, including melanoma and hepatocellular carcinoma, by converging attacks from both inside and outside the tumor tissues.


  • Lyophilized lymph nodes for improved delivery of chimeric antigen receptor T cells

    by Jiaqi Shi, Wei Wu, Dong Chen, Ziyan Liao, Tao Sheng, Yanfang Wang, Yuejun Yao, Qing Wu, Feng Liu, Ruyi Zhou, et al.

    Lymph nodes are crucial organs of the adaptive immune system, orchestrating T cell priming, activation and tolerance. T cell activity and function are highly regulated by lymph nodes, which have a unique structure harbouring distinct cells that work together to detect and respond to pathogen-derived antigens. Here we show that implanted patient-derived freeze-dried lymph nodes loaded with chimeric antigen receptor T cells improve delivery to solid tumours and inhibit tumour recurrence after surgery. Chimeric antigen receptor T cells can be effectively loaded into lyophilized lymph nodes, whose unaltered meshwork and cytokine and chemokine contents promote chimeric antigen receptor T cell viability and activation. In mouse models of cell-line-derived human cervical cancer and patient-derived pancreatic cancer, delivery of chimeric antigen receptor T cells targeting mesothelin via the freeze-dried lymph nodes is more effective in preventing tumour recurrence when compared to hydrogels containing T-cell-supporting cytokines. This tissue-mediated cell delivery strategy holds promise for controlled release of various cells and therapeutics with long-term activity and augmented function.


  • Open Access

    Rationally designed approaches to augment CAR-T therapy for solid tumor treatment

    by Chaojie Zhu, Qing Wu, Tao Sheng, Jiaqi Shi, Xinyuan Shen, Jicheng Yu, Yang Du, Jie Sun, Tingxizi Liang, Kaixin He, et al.

    Chimeric antigen receptor T cell denoted as CAR-T therapy has realized incredible therapeutic advancements for B cell malignancy treatment. However, its therapeutic validity has yet to be successfully achieved in solid tumors. Different from hematological cancers, solid tumors are characterized by dysregulated blood vessels, dense extracellular matrix, and filled with immunosuppressive signals, which together result in CAR-T cells’ insufficient infiltration and rapid dysfunction. The insufficient recognition of tumor cells and tumor heterogeneity eventually causes cancer reoccurrences. In addition, CAR-T therapy also raises safety concerns, including potential cytokine release storm, on-target/off-tumor toxicities, and neuro-system side effects. Here we comprehensively review various targeting aspects, including CAR-T cell design, tumor modulation, and delivery strategy. We believe it is essential to rationally design a combinatory CAR-T therapy via constructing optimized CAR-T cells, directly manipulating tumor tissue microenvironments, and selecting the most suitable delivery strategy to achieve the optimal outcome in both safety and efficacy.


  • Open Access

    Engineered bacteria for augmented in situ tumor vaccination

    by Xinyuan Shen, Chaojie Zhu, Xutao Liu, Hanqi Zheng, Qing Wu, Jijin Xie, Hao Huang, Ziyan Liao, Jiaqi Shi, Kewang Nan, et al.

    Engineered bacteria can be leveraged for in situ tumor vaccinations with their tumor-targeting ability and adjuvanticity. Engineering strategies like chemical modification, nanotechnology, and genetic engineering improve their safety and efficacy.


  • Open Access

    Recent Advances of Nanotechnology-Facilitated Bacteria-Based Drug and Gene Delivery Systems for Cancer Treatment

    by Chaojie Zhu, Zhiheng Ji, Junkai Ma, Zhijie Ding, Jie Shen, Qiwen Wang

    Cancer is one of the most devastating and ubiquitous human diseases. Conventional therapies like chemotherapy and radiotherapy are the most widely used cancer treatments. Despite the notable therapeutic improvements that these measures achieve, disappointing therapeutic outcome and cancer reoccurrence commonly following these therapies demonstrate the need for better alternatives. Among them, bacterial therapy has proven to be effective in its intrinsic cancer targeting ability and various therapeutic mechanisms that can be further bolstered by nanotechnology. In this review, we will discuss recent advances of nanotechnology-facilitated bacteria-based drug and gene delivery systems in cancer treatment. Therapeutic mechanisms of these hybrid nanoformulations are highlighted to provide an up-to-date understanding of this emerging field.


  • Open Access

    Recent Advances of Cell Membrane Coated Nanoparticles in Treating Cardiovascular Disorders

    by Chaojie Zhu, Junkai Ma, Zhiheng Ji, Jie Shen, Qiwen Wang

    Cardiovascular diseases (CVDs) are the leading cause of death worldwide, causing approximately 17.9 million deaths annually, an estimated 31% of all deaths, according to the WHO. CVDs are essentially rooted in atherosclerosis and are clinically classified into coronary heart disease, stroke and peripheral vascular disorders. Current clinical interventions include early diagnosis, the insertion of stents, and long-term preventive therapy. However, clinical diagnostic and therapeutic tools are subject to a number of limitations including, but not limited to, potential toxicity induced by contrast agents and unexpected bleeding caused by anti-platelet drugs. Nanomedicine has achieved great advancements in biomedical area. Among them, cell membrane coated nanoparticles, denoted as CMCNPs, have acquired enormous expectations due to their biomimetic properties. Such membrane coating technology not only helps avoid immune clearance, but also endows nanoparticles with diverse cellular and functional mimicry. In this review, we will describe the superiorities of CMCNPs in treating cardiovascular diseases and their potentials in optimizing current clinical managements.